Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ETREAT: A Prospective Observational Study to Evaluate the Effectiveness of Botulinum Toxin Type A (BoNT-A) Injections in Patients With Post-stroke Upper and/or Lower Limb Spasticity in the Early Stage of Spasticity Development.

NCT02275312 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT02275312
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02275312 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ETREAT: A Prospective Observational Study to Evaluate the Effectiveness of Botulinum Toxin Type A (BoNT-A) Injections in Patients With Post-stroke Upper and/or Lower Limb Spasticity in the Early Stage of Spasticity Development.
Lead sponsor
Ipsen
Phase
Observational
Overall status
Completed
Start date
July 31, 2014
Completion date
July 31, 2017
Enrollment
110 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

spasticity